Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atea Pharmaceuticals, Inc.AVIR · Entity 5580 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atea Pharmaceuticals, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,806 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 29,600 · Balance 124,806 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 29,600 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: The RSUs vested in full on June 18, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,700 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 26,700 · Balance 26,700 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2036-06-17 | Direct | 37,700 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 37,700 · Balance 37,700 F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: The RSUs vested in full on June 18, 2026.
F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 37,700 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001193125-26-279719 · ownership.xml · derivative · entry 4 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,700 Underlying: Common Stock · 37,700 shares Expires 2036-06-17 F4 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279719 · ownership.xml · derivative · entry 3 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F3 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279719 · ownership.xml · derivative · entry 2 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in full on June 18, 2026. F2 · derivative.expiration_date: The RSUs vested in full on June 18, 2026. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279719 · ownership.xml · nonDerivative · entry 1 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089605 · ownership.xml · derivative · entry 4 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vested in full on June 20, 2025. F4 · derivative.expiration_date: The restricted stock units vested in full on June 20, 2025. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0000950170-25-089605 · ownership.xml · derivative · entry 3 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2035-06-19 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089605 · ownership.xml · derivative · entry 2 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 29,600 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089605 · ownership.xml · nonDerivative · entry 1 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 21:59 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0000950170-24-076379 · ownership.xml · derivative · entry 3 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2034-06-20 F4 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 21:59 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076379 · ownership.xml · derivative · entry 2 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 29,600 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F3 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 21:59 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | SaleCommon Stock | 17,544 | $3.49 | $61,144.35 |
DisclosureSEC source: 0000950170-24-076379 · ownership.xml · nonDerivative · entry 1 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,606 F1 · price: The shares were sold solely to cover taxes upon the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.43 to $3.53, inclusive. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 33,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074986 · ownership.xml · derivative · entry 2 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units are fully vested. F3 · derivative.expiration_date: The restricted stock units do not have an expiration date. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 33,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074986 · ownership.xml · nonDerivative · entry 1 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 46,750 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0000899243-23-016128 · doc4.xml · derivative · entry 2 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,750 Underlying: Common Stock · 46,750 shares Expires 2033-06-15 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 16, 2023, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 33,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-016128 · doc4.xml · derivative · entry 1 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,150 Underlying: Common Stock · 33,150 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 23:45 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 61,264 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0000899243-22-023496 · doc4.xml · derivative · entry 1 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,264 Underlying: Common Stock · 61,264 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) equal monthly installments following June 17, 2022, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 21:36 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 34,025 | $0.00 Strike: $23.39 | $0.00 |
DisclosureSEC source: 0000899243-21-025049 · doc4.xml · derivative · entry 1 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,025 Underlying: Common Stock · 34,025 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) equal monthly installments following June 18, 2021, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 21:43 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000899243-20-029956 · doc4.xml · derivative · entry 1 Polsky Bruce · CIK 0001508458 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-10-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments following October 29, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.